Omnyx, LLC Announces Strategic Collaborations In Conjunction with New Dynamyx™ Software Launch

Omnyx, LLC Announces Strategic Collaborations

In Conjunction with New Dynamyx™

Software Launch

Visiopharm® Breast Panel Algorithms and Desktop Scanner Integration

with Objective Imaging™ Expand Digital Pathology Offering

 

PITTSBURGH, March 16, 2016 — Omnyx, LLC, a joint venture of GE Healthcare and UPMC, is announcing two strategic collaborations in conjunction with the launch of its next generation digital pathology software, Dynamyx™. 

“Over the last year, we have worked closely with Visiopharm® to move from great ideas to a product set that realizes our mutual vision to enhance image analysis for breast cancer. This signifies the first step in a continued commitment on the part of both companies to create value for our mutual customers,” said Mamar Gelaye, CEO of Omnyx.

Precision, Quantification and Confidence in Decision-Making
Dynamyx software aids clinicians in performing various tasks and delivers more utility for pathologists to help make confident decisions and adapt to a digital workflow through the use of intuitive design and enhanced tools. The Dynamyx software advances cancer diagnostics with clinically validated image analysis algorithms for pathologists from Visiopharm. The integration of Visiopharm’s breast panel analysis algorithms (HER2, ER, PR, Ki67) further strengthens Omnyx’s existing relationship with Visiopharm, which was first announced in 2013. These algorithms give pathologists additional insights when evaluating certain breast tissue, helping to standardize data and produce concise and consistent results.

“Omnyx has a comprehensive workflow solution, and incorporating image analysis is essential to fulfilling the promise of digitization to pathologists,” said Michael Grunkin, CEO and Founder of Visiopharm.

 Compact Scanner Integration
Further increasing user options, the Omnyx Dynamyx software now includes integration with the Objective Imaging™ Desktop Scanner providing image viewing continuity through the use of the single Omnyx viewer. In addition to being ideal for smaller workspaces and collaborating remotely, this scanner enables new applications for digital pathology, such as consults, education, research and small use cases.

Omnyx and Objective Imaging have been working together throughout the past year on this joint product release, including achieving regulatory milestones such as the recent CE mark for the Desktop Scanner, and a commercial model in support of Omnyx’s distribution of Objective Imaging’s product.

“The integration of the Objective Imaging Desktop Scanner with the new Omnyx Dynamyx platform represents an important step forward in increasing the value of high-performance whole slide imaging in the market. Our collaboration expands the availability of innovative, high-quality digital pathology solutions that benefit both pathologists and their patients,” said Don Laferty, President of Objective Imaging.

“Objective Imaging has long-standing capabilities in scanning components, and their recent release of a fully integrated desktop scanner offers Omnyx’s customers the versatility to connect distributed networks of pathologists for consultations,” added Gelaye. “We are excited to collaborate and make these capabilities more accessible to pathologists.”

 The added capability and advances of the new Dynamyx software and our strategic collaborations are best presented through a demonstration. Please visit us March 14-16 at booth #1122 at the USCAP Annual Meeting in Seattle to view Dynamyx, or contact us at www.Omnyx.com.

About Omnyx
Omnyx, LLC, a joint venture of GE Healthcare and UPMC, is helping to transform the way pathologists worldwide work and collaborate. Through our Precision Solution™ that includes smart scanners, brilliant software and transformative consulting, all members of the cancer care team can work together to enhance patient outcomes. Our vision is a world in which efficient and effective cancer diagnosis helps guide personalized patient care. Omnyx® products are for in vitro diagnostic use for specific clinical applications and are intended for research use only on other applications. For more information, visit www.Omnyx.com.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. www.gehealthcare.com.

About UPMC
A world-renowned health care provider and insurer, Pittsburgh-based UPMC is inventing new models of patient-centered, cost-effective, accountable care. It provides more than $888 million a year in benefits to its communities, including more care to the region’s most vulnerable citizens than any other health care institution. The largest nongovernmental employer in Pennsylvania, UPMC integrates 60,000 employees, more than 20 hospitals, more than 500 doctors’ offices and outpatient sites, a 2.9-million-member health insurance division, and international and commercial operations. Affiliated with the University of Pittsburgh Schools of the Health Sciences, UPMC ranks No. 13 in the prestigious U.S. News & World Report annual Honor Roll of America’s Best Hospitals. For more information, go to UPMC.com.

In the European Union, the Omnyx® Precision Solution™ is CE marked under the European Union’s ‘In Vitro Diagnostics Directive’ for in vitro diagnostic use with the VL4 and VL120 scanners, and DPS and Dynamyx™ software. In the European Union, the Objective Imaging Desktop™ Scanner is CE marked under the European Union’s ‘In Vitro Diagnostics Directive’ for in vitro diagnostic use.

 In Canada, the Omnyx Precision Solution is licensed by Health Canada for in vitro diagnostic use with the VL4 and VL120 scanners, and DPS and Dynamyx software. In Canada, the Objective Imaging Desktop Scanner is for research use only.

 In the United States, the Omnyx Precision Solution, consisting of DPS and the VL4 scanner, is cleared by the U.S. Food & Drug Administration for in vitro diagnostic use for Manual Read of the Digital HER2 Application. In the United States, the VL120 scanner and Dynamyx software are for research use only. In the United States, the Objective Imaging Desktop Scanner is for research use only.

 Visiopharm® ONCOtopix™ breast panel algorithms are CE marked for diagnostic use in Europe. These algorithms are for research use only and not approved for use in diagnostic procedures in the United States and Canada.

 ###

MEDIA CONTACT:
Lori Lukus
412-874-3969 (cell)
Lori.Lukus@Omnyx.com